(Q33272746)

25 July 2017

title

Treatment of diabetic macular edema with intravitreal triamcinolone acetonide injection: functional and anatomical outcomes (English)

1 reference

25 July 2017

main subject

diabetic macular edema

1 reference

Selim Kocabora M

1

1 reference

25 July 2017

Kucuksahin H

2

1 reference

25 July 2017

Gulkilik G

3

1 reference

25 July 2017

Taskapili M

4

1 reference

25 July 2017

Yilmazli C

5

1 reference

25 July 2017

Engin G

6

1 reference

25 July 2017

publication date

1 January 2007

1 reference

Journal Francais d'Ophtalmologie

25 July 2017

published in

1 reference

25 July 2017

volume

30

1 reference

25 July 2017

issue

1

1 reference

25 July 2017

page(s)

32-38

1 reference

Photocoagulation for Diabetic Macular Edema

25 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0181-5512%2807%2989547-7

7 January 2021

Modified grid laser photocoagulation for diffuse diabetic macular edema. Long-term visual results

1 reference

https://api.crossref.org/works/10.1016%2FS0181-5512%2807%2989547-7

7 January 2021

Diabetic Macular Edema and Argon Laser Photocoagulation: A Prospective Randomized Study

1 reference

https://api.crossref.org/works/10.1016%2FS0181-5512%2807%2989547-7

7 January 2021

Diabetic macular edema. A review

1 reference

https://api.crossref.org/works/10.1016%2FS0181-5512%2807%2989547-7

7 January 2021

A permeability defect of the retinal pigment epithelium. Occurrence in early streptozocin diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0181-5512%2807%2989547-7

7 January 2021

The role of the vitreous in diabetic macular edema

1 reference

https://api.crossref.org/works/10.1016%2FS0181-5512%2807%2989547-7

7 January 2021

Corticosteroids inhibit VEGF-induced vascular leakage in a rabbit model of blood-retinal and blood-aqueous barrier breakdown

1 reference

https://api.crossref.org/works/10.1016%2FS0181-5512%2807%2989547-7

7 January 2021

Vitreous concentrations of triamcinolone acetonide in human eyes after intravitreal or subtenon injection

1 reference

https://api.crossref.org/works/10.1016%2FS0181-5512%2807%2989547-7

7 January 2021

Clearance of triamcinolone from vitreous

1 reference

https://api.crossref.org/works/10.1016%2FS0181-5512%2807%2989547-7

7 January 2021

Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection

1 reference

https://api.crossref.org/works/10.1016%2FS0181-5512%2807%2989547-7

7 January 2021

Pharmacokinetic-pharmacodynamic modeling of the effect of triamcinolone acetonide on central macular thickness in patients with diabetic macular edema

1 reference

https://api.crossref.org/works/10.1016%2FS0181-5512%2807%2989547-7

7 January 2021

Intravitreal injection of dexamethasone. Treatment of experimentally induced endophthalmitis

1 reference

https://api.crossref.org/works/10.1016%2FS0181-5512%2807%2989547-7

7 January 2021

The lack of toxicity of intravitreally administered triamcinolone acetonide

1 reference

https://api.crossref.org/works/10.1016%2FS0181-5512%2807%2989547-7

7 January 2021

Intravitreal triamcinolone acetonide

1 reference

https://api.crossref.org/works/10.1016%2FS0181-5512%2807%2989547-7

7 January 2021

Diffuse diabetic macular oedema treated by intravitreal triamcinolone acetonide: a comparative, non-randomised study

1 reference

https://api.crossref.org/works/10.1016%2FS0181-5512%2807%2989547-7

7 January 2021

Intravitreal triamcinolone for refractory diabetic macular edema

1 reference

https://api.crossref.org/works/10.1016%2FS0181-5512%2807%2989547-7

7 January 2021

Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0181-5512%2807%2989547-7

7 January 2021

Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0181-5512%2807%2989547-7

7 January 2021

Intravitreal triamcinolone as a primary therapy in diabetic macular oedema

1 reference

https://api.crossref.org/works/10.1016%2FS0181-5512%2807%2989547-7

7 January 2021

Intravitreal triamcinolone acetonide and intraocular pressure

1 reference

https://api.crossref.org/works/10.1016%2FS0181-5512%2807%2989547-7

7 January 2021

Intraocular pressure elevation after intravitreal triamcinolone acetonide injection

1 reference

https://api.crossref.org/works/10.1016%2FS0181-5512%2807%2989547-7

7 January 2021

Dosage dependency of intravitreal triamcinolone acetonide as treatment for diabetic macular oedema

1 reference

https://api.crossref.org/works/10.1016%2FS0181-5512%2807%2989547-7

7 January 2021

Early rapid rise in intraocular pressure after intravitreal triamcinolone acetonide injection

1 reference

https://api.crossref.org/works/10.1016%2FS0181-5512%2807%2989547-7

7 January 2021

Vitrectomy as a treatment for elevated intraocular pressure following intravitreal injection of triamcinolone acetonide

1 reference

https://api.crossref.org/works/10.1016%2FS0181-5512%2807%2989547-7

7 January 2021

Complications of intravitreal injection of triamcinolone acetonide

1 reference

https://api.crossref.org/works/10.1016%2FS0181-5512%2807%2989547-7

7 January 2021

Clinical characteristics and surgical outcomes of pediatric rhegmatogenous retinal detachment in Taiwan

1 reference

https://api.crossref.org/works/10.1016%2FS0181-5512%2807%2989547-7

7 January 2021

Intravitreal triamcinolone-induced elevated intraocular pressure is associated with the development of posterior subcapsular cataract

1 reference

https://api.crossref.org/works/10.1016%2FS0181-5512%2807%2989547-7

7 January 2021

Pseudo-endophthalmitis after intravitreal injection of triamcinolone

1 reference

https://api.crossref.org/works/10.1016%2FS0181-5512%2807%2989547-7

7 January 2021

Pseudohypopyon after intravitreal triamcinolone acetonide injection for cystoid macular edema

1 reference

https://api.crossref.org/works/10.1016%2FS0181-5512%2807%2989547-7

7 January 2021

Noninfectious endophthalmitis associated with intravitreal triamcinolone injection

1 reference

https://api.crossref.org/works/10.1016%2FS0181-5512%2807%2989547-7

7 January 2021

Comparison of different techniques for purification of triamcinolone acetonide suspension for intravitreal use.

1 reference

https://api.crossref.org/works/10.1016%2FS0181-5512%2807%2989547-7

7 January 2021

Acute endophthalmitis following intravitreal triamcinolone acetonide injection

1 reference

https://api.crossref.org/works/10.1016%2FS0181-5512%2807%2989547-7

7 January 2021

Acute endophthalmitis incidence: intravitreal triamcinolone

1 reference

https://api.crossref.org/works/10.1016%2FS0181-5512%2807%2989547-7

7 January 2021

Dexamethasone sustained drug delivery implant for the treatment of severe uveitis

1 reference

https://api.crossref.org/works/10.1016%2FS0181-5512%2807%2989547-7

7 January 2021

Fluocinolone acetonide sustained drug delivery device to treat severe uveitis

1 reference

https://api.crossref.org/works/10.1016%2FS0181-5512%2807%2989547-7

7 January 2021

10.1016/S0181-5512(07)89547-7

Identifiers

DOI

1 reference

25 July 2017

1 reference